Trending

J&J

FDA clears cardiovascular claim for J&J’s Invokana

Johnson & Johnson finally has some good news to report for its diabetes blockbuster Invokana, after the FDA

X

FDA clears cardiovascular claim for J&J’s Invokana

https://pharmaphorum.com/news/fda-clears-cardiovascular-claim-for-jjs-invokana/

J&J preps for FDA panel grilling over depression drug

J&J preps for FDA panel grilling over depression drug

Johnson & Johnson is “confident” about regulatory reviews of its depression drug esketamine ahead of a likely grilling

X

J&J preps for FDA panel grilling over depression drug

https://pharmaphorum.com/news/janssen-preps-for-fda-panel-grilling-esketamine/

New data sets up potential new gastro use for J&J’s Stelara

New data sets up potential new gastro use for J&J’s Stelara

Janssen’s Stelara has shown positive results in an ulcerative colitis (UC) trial, setting up a potential new indication

X

New data sets up potential new gastro use for J&J’s Stelara

https://pharmaphorum.com/news/new-data-sets-up-potential-new-gastro-use-for-jjs-stelara/

Johnson & Johnson leads the way to a world without disease

Johnson & Johnson leads the way to a world without disease

Cat Oyler, Global Head of External Innovation Strategy and Operations at Johnson & Johnson (J&J), has an ambitious

X

Johnson & Johnson leads the way to a world without disease

https://pharmaphorum.com/views-analysis-digital/world-without-disease-johnson-johnson-leads/

FDA approves Janssen’s HIV combination Symtuza

FDA approves Janssen’s HIV combination Symtuza

Janssen has won US approval for its once-daily HIV pill Symtuza (D/C/F/TAF), which it hopes will improve patient

X

FDA approves Janssen’s HIV combination Symtuza

https://pharmaphorum.com/news/fda-janssen-hiv-symtuza/

J&J seals $2.1bn deal on sale of major diabetes devices firm

J&J seals $2.1bn deal on sale of major diabetes devices firm

As part of its ongoing divestment program, a deal worth $2.1 billion has been struck between Johnson &

X

J&J seals $2.1bn deal on sale of major diabetes devices firm

https://pharmaphorum.com/news/jj-deal-glucose-monitoring-system/

J&J offered $2.7 billion for sterilisation business by Fortive

Johnson & Johnson (J&J) has announced that Fortive Corp has made an offer of about $2.7 billion in cash for its Advanced Sterilisation Products (ASP) business.

X

J&J offered $2.7 billion for sterilisation business by Fortive

https://pharmaphorum.com/news/jnj-sterilisation-business-fortive/

Top pharmaceutical companies in the world in 2017

Top pharmaceutical companies in the world in 2017

The rankings of the top pharmaceutical companies in the world in 2017 presented a mixed picture, with stability

X

Top pharmaceutical companies in the world in 2017

https://pharmaphorum.com/views-and-analysis/top-pharmaceutical-companies-world-2017/

J&J ups forecast after keeping biosimilars at bay

Johnson and Johnson has posted stronger than expected Q3 results, helped by it riding out biosimilar challenges and

X

J&J ups forecast after keeping biosimilars at bay

https://pharmaphorum.com/news/jj-q3-biosimilars/

1 2

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com